{
    "nct_id": "NCT06850597",
    "title": "Randomized, Double-blind, Placebo- Controlled Trial Evaluating Efficacy and Safety of Dimethyl Fumarate in Brain Atrophy Reduction, Synaptic Functional Connectivity, Cognitive Functions, Quality of Life, and Activity of Daily Living Improvement Among Patients with Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease",
    "status": "RECRUITING",
    "last_update_time": "2025-02-24",
    "description_brief": "The goal of this clinical trial is to assess the degree of improvement in cognitive functions, including memory, attention, thinking, executive and language functions in diagnosed patients MCI and AD taking dimethyl fumarate 480 mg daily compared to patients taking placebo. Participant will be 55 to 90 years old, both genders. The main question it aims to answer is: Changing the degree of cognitive improvement based on the RBANS score among patients diagnosed with MCI and AD after completing dimethyl fumarate therapy test group compared to the placebo group.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "Disease-targeted small molecule",
    "drug": [
        "Dimethyl fumarate (DMF; brand: Tecfidera)"
    ],
    "placebo": [
        "Placebo"
    ],
    "explanation_target": [
        "Reason: The trial tests dimethyl fumarate (DMF) in MCI/Alzheimer\u2019s patients and aims to change disease-related measures (brain atrophy, synaptic connectivity) and cognition. DMF is a small\u2011molecule fumaric acid ester with immunomodulatory, antioxidant and neuroprotective effects that acts mainly via activation of the Nrf2 antioxidant pathway and related anti\u2011inflammatory mechanisms; it is marketed for multiple sclerosis (Tecfidera). \ue200cite\ue202turn0search5\ue202turn0search3\ue201",
        "Act: Key extracted details \u2014 intervention: dimethyl fumarate 480 mg daily; comparator: placebo; population: 55\u201390 y with MCI and AD; endpoints: cognitive function (RBANS), brain atrophy, synaptic connectivity, QoL/ADL. Preclinical and translational studies report DMF can reduce neuroinflammation, oxidative stress and amyloid\u2011related damage and improve cognition in AD model systems, supporting a disease\u2011targeting (pathology\u2011modifying) mechanism rather than a purely symptomatic cognitive enhancer. Based on drug type (small molecule) and mechanism (Nrf2/anti\u2011inflammatory, neuroprotective), the correct category is disease\u2011targeted small molecule. \ue200cite\ue202turn0search2\ue202turn0search1\ue201",
        "Reflect: The trial\u2019s clinical endpoints include structure (atrophy) and synaptic/connectivity measures in addition to cognition, which aligns with a disease\u2011modifying intent. Although the primary clinical readout is cognitive improvement, DMF\u2019s known biology (small\u2011molecule Nrf2 activator with anti\u2011inflammatory/neuroprotective effects) supports classification as a disease\u2011targeted small molecule being repurposed for AD. If future information showed the trial\u2019s purpose was only symptomatic cognitive enhancement without any disease\u2011pathology endpoints, classification could be reconsidered, but given the title and endpoints provided, \u2018\u2018Disease\u2011targeted small molecule\u2019\u2019 is the best fit. \ue200cite\ue202turn0search4\ue202turn0search1\ue201"
    ],
    "agent_type": "G) Oxidative Stress",
    "explanation_agent": [
        "Reason: The investigational drug dimethyl fumarate (DMF; Tecfidera) is a small electrophilic fumaric acid ester whose principal, well\u2011characterized mechanism is activation of the Nrf2 (NFE2L2) antioxidant transcriptional pathway \u2014 increasing expression of antioxidant enzymes and reducing oxidative stress \u2014 while also exerting anti\u2011inflammatory/immunomodulatory effects. This Nrf2/antioxidant action maps most directly to CADRO category G) Oxidative Stress (with secondary overlap with F) Inflammation). \ue200cite\ue202turn0search2\ue202turn0search3\ue201",
        "Act: Key extracted details from the trial description \u2014 intervention: dimethyl fumarate 480 mg daily (small molecule); population: MCI and AD; endpoints: brain atrophy, synaptic connectivity, cognition, QoL/ADL \u2014 and supporting literature: DMF activates Nrf2, reduces reactive oxygen species and neuroinflammation, and shows benefit in AD model systems (reduced amyloid\u2011related damage, improved memory/atrophy measures). Because the drug\u2019s dominant mechanism is antioxidant/Nrf2 activation (a therapy aimed at oxidative stress and neuroprotection), the most specific CADRO classification is G) Oxidative Stress. \ue200cite\ue202turn0search0\ue202turn0search5\ue201",
        "Reflect: Confirmation and caveats \u2014 DMF has clear anti\u2011inflammatory actions (inhibition of NF\u2011\u03baB and microglial activation) so there is mechanistic overlap with CADRO F) Inflammation; however, Nrf2 activation (oxidative stress response) is the canonical, primary biochemical target for DMF and the basis for its repurposing in neurodegeneration, making G) Oxidative Stress the best single category. If a panel-based decision required multiple categories because the protocol explicitly targeted both pathways equally, R) Multi\u2011target could be considered, but given the trial text and DMF biology, G) is the most specific fit. \ue200cite\ue202turn0search6\ue202turn0search8\ue201",
        "Web-search evidence (selected sources supporting the mechanism and AD preclinical data): 1) DMF activates NRF2 and is an approved small\u2011molecule drug (Tecfidera) with electrophilic KEAP1 modification -> review of NRF2 and DMF. \ue200cite\ue202turn0search2\ue201 2) Preclinical AD studies: DMF activates Nrf2, reduces oxidative stress, inflammation and amyloid\u2011related damage, and ameliorates memory/atrophy in AD models. \ue200cite\ue202turn0search0\ue201 3) Experimental evidence of DMF triggering Nrf2 and lowering ROS in human cells. \ue200cite\ue202turn0search3\ue201 4) Reviews summarizing DMF\u2019s antioxidant and anti\u2011inflammatory neuroprotective actions and rationale for repurposing in neurodegeneration. \ue200cite\ue202turn0search5\ue202turn0search4\ue201"
    ]
}